The Globe and Mail reports in its Tuesday, March 11, edition that RBC's Douglas Miehm has reaffirmed his "outperform" recommendation for Oncolytics Biotech. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm cut his share target back from $6 to $5. Analysts on average target the shares at $6.20. Mr. Miehm says in a note: "Oncolytics Biotech is planning to enroll 180 HR+/HER2-mBC patients in a large Ph2 clinical trial that the company anticipates will support an accelerated approval of pela in breast cancer. Management anticipates that it can generate the primary endpoint (PFS) within two years following the start of patient enrollment, which is expected in H2/25. Oncolytics Biotech presented two posters focusing on research in anal and pancreatic cancers at the ASCO Gastrointestinal Cancers Symposium held in San Francisco in January, 2025, highlighting pela's potential across multiple indications. Price target to $5 as we incorporate equity financing and corresponding dilution." The Globe reported on April 5 that Raymond James analyst Rahul Sarugaser had commenced coverage on Oncolytics Biotech with an "outperformer" recommendation and $3 share target. It was then worth $1.56.